Sensitivity (+) |
ER positive,
HER2-negative,
PIK3CA somatic variants
|
Invasive Breast Carcinoma |
Alpelisib,
Fulvestrant
|
|
Sensitivity (+) |
HER2-negative,
PIK3CA somatic variants,
PR positive
|
Invasive Breast Carcinoma |
Alpelisib,
Fulvestrant
|
|
Sensitivity (+) |
ER positive,
HER2-negative,
PIK3CA somatic variants,
PR positive
|
Invasive Breast Carcinoma |
Alpelisib,
Fulvestrant
|
|
Sensitivity (+) |
ER positive,
HER2-negative,
PIK3CA somatic variants
|
Invasive Breast Carcinoma |
Capivasertib,
Fulvestrant
|
|
Sensitivity (+) |
HER2-negative,
PIK3CA somatic variants,
PR positive
|
Invasive Breast Carcinoma |
Capivasertib,
Fulvestrant
|
|
Sensitivity (+) |
ER positive,
HER2-negative,
PIK3CA somatic variants,
PR positive
|
Invasive Breast Carcinoma |
Capivasertib,
Fulvestrant
|
|
Sensitivity (+) |
ER positive,
HER2-negative,
PIK3CA somatic variants
|
Invasive Breast Carcinoma |
Fulvestrant,
Inavolisib,
Palbociclib
|
|
Sensitivity (+) |
HER2-negative,
PIK3CA somatic variants,
PR positive
|
Invasive Breast Carcinoma |
Fulvestrant,
Inavolisib,
Palbociclib
|
|
Sensitivity (+) |
ER positive,
HER2-negative,
PIK3CA somatic variants,
PR positive
|
Invasive Breast Carcinoma |
Fulvestrant,
Inavolisib,
Palbociclib
|
|
Sensitivity (+) |
ER positive,
HER2-negative,
PIK3CA somatic variants
|
Invasive Breast Carcinoma |
Alpelisib,
Fulvestrant
|
|
Sensitivity (+) |
HER2-negative,
PIK3CA somatic variants,
PR positive
|
Invasive Breast Carcinoma |
Alpelisib,
Fulvestrant
|
|
Sensitivity (+) |
ER positive,
HER2-negative,
PIK3CA somatic variants,
PR positive
|
Invasive Breast Carcinoma |
Alpelisib,
Fulvestrant
|
|
Sensitivity (+) |
ER positive,
HER2-negative,
PIK3CA somatic variants
|
Invasive Breast Carcinoma |
Capivasertib,
Fulvestrant
|
|
Sensitivity (+) |
ER positive,
HER2-negative,
PIK3CA amplification
|
Invasive Breast Carcinoma |
Capivasertib,
Fulvestrant
|
|